The DOI matches its Crossref record; 103 of the 114 references it cites were found in a registry or an index; 52 of the 97 sources its claims cite were checked for support.
Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review
Open accessAbstract
Background: Malignant-associated abdominal wall endometriosis (AWE) is a rare pathology, likely to occur in 1% of scar endometriosis. The objectives of this study were to update the evidence on tumor degeneration arising from AWE to notify about the clinical characteristics, the different treatments offered to patients and their outcomes. Methods: A comprehensive systematic review of the literature was conducted. PubMed, Embase and Cochrane Library databases were used. Prospero (ID number: CRD42024505274). Results: Out of the 152 studies identified, 63 were included, which involved 73 patients. The main signs and symptoms were a palpable abdominal mass (85.2%) and cyclic pelvic pain (60.6%). The size of the mass varied between 3 and 25 cm. Mean time interval from the first operation to onset of malignant transformation was 20 years. Most common cancerous histological types were clear cell and endometrioid subtypes. Most widely accepted treatment is the surgical resection of local lesions with wide margins combined with adjuvant chemotherapy. The prognosis for endometriosis-associated malignancy in abdominal wall scars is poor, with a five-year survival rate of around 40%. High rates of relapse have been reported. Conclusions: Endometrial implants in the abdominal wall should be considered as preventable complications of gynecological surgeries. Special attention should be paid to women with a history of cesarean section or uterine surgery.
Overview
CoChat Summary
## TL;DR
This systematic review compiled 73 cases from 63 studies of malignant transformation in abdominal wall endometriosis and found that the condition is rare but often diagnosed late, with a mean 20-year interval from first surgery to malignancy. The most common histology was clear cell carcinoma (52/73), and outcomes were poor with 37.9% relapse and 22.4% mortality among those followed.
## Key findings
- The review included 73 patients from 63 studies; the median age at malignant transformation diagnosis was 47 years (range 37–67).
- The mean interval from first surgery to malignant transformation was 19.9 years; the longest reported interval was 41 years.
- The most frequent malignant histology was clear cell carcinoma (52/73), followed by endometrioid adenocarcinoma (11/73).
- Among 58 patients with follow-up, 22/58 (37.9%) relapsed, 13/58 (22.4%) died of disease, and complete remission was achieved in 36/58 (62.1%).
- The authors report a 5-year survival rate around 40% for endometriosis-associated malignancy in abdominal wall scars.
## Methods
- Systematic review performed according to PRISMA 2020 and prospectively registered in PROSPERO (CRD42024505274).
- Searched PubMed, Embase, and Cochrane Library from March 1946 to March 2023; included studies in English and French with sufficient reporting data.
- Extracted clinical, imaging, treatment, follow-up, and outcome variables from eligible studies; descriptive statistics and group comparisons were performed in R and survival analysis with Kaplan–Meier methods.
## Limitations
- The authors state the main limitation was the rarity of the disease, leading to mostly case reports with heterogeneous information, which limited statistical analysis, meta-analysis, and subgroup variance analysis.
- Evident from the text: the evidence base is small and observational, with no randomized comparisons and missing data for some variables, so treatment-effect conclusions are weak.
- Evident from the text: the review is limited to English and French studies, which may have excluded relevant reports.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
34 Valid · 5 Not valid · 29 Not checked · 82 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, atypical endometriosis was found as the precursor of endometrioid ovarian cancer and clear cell cancer in 15–32% of the cases [20,21,22].”
§ Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review > 4. Discussion
What the sources say
- Partly supportedcites [20] Kawahara, N., Miyake, R., Yamanaka, S., and Kobayashi, H. (2021). A Novel Predictive Tool for Discriminating Endometriosis Associated Ovarian Cancer from Ovarian Endometrioma: The R2 Predictive Index. Cancers, 13. sourceExperimental — accuracy not yet measured
The Simple Summary calls ovarian endometrioma a precancerous condition for endometriosis-associated ovarian cancer, and the Case Report describes endometrioid carcinoma within an endometrioma. Neither passage identifies atypical endometriosis as the precursor or gives the claimed 15–32% figure; searches for those terms found no supporting passage. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [21] Hitti, 1990, Clear cell carcinoma arising in extraovarian endometriosis: Report of three cases and review of the literature, Gynecol. Oncol. source
- Not checked — no full text of the sourcecites [22] Schnieber, 1986, Maligne Entartung einer extragenitalen Endometriose [Malignant transformation of extragenital endometriosis], Geburtshilfe Frauenheilkd source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ovarian and/or pelvic endometriosis is associated with approximately 42% of endometrioid ovarian cancer [18,19,20,21].”
§ Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review > 4. Discussion
What the sources say
- Could not verifycites [18] Scholler, 2007, CA125 in ovarian cancer, Biomark. Med. sourceExperimental — accuracy not yet measured
The Introduction discusses ovarian cancer and the possible fallopian-tube origin of serous tumors, while the Conclusions references mention endometriosis in relation to CA125. Searches for endometrioid ovarian cancer, endometriosis, and 42% found no passage in our copy reporting the claimed association or percentage. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [19] Vergote, 2005, Port-site metastases after open laparoscopy: A study in 173 patients with advanced ovarian carcinoma, Int. J. Gynecol. Cancer source
- Partly supportedcites [20] Kawahara, N., Miyake, R., Yamanaka, S., and Kobayashi, H. (2021). A Novel Predictive Tool for Discriminating Endometriosis Associated Ovarian Cancer from Ovarian Endometrioma: The R2 Predictive Index. Cancers, 13. sourceExperimental — accuracy not yet measured
The Introduction links endometriosis in the pelvic peritoneum or ovaries to subsequent endometriosis-associated ovarian cancer, and the Case Report describes endometrioid carcinoma within an endometrioma. Neither passage establishes that approximately 42% of endometrioid ovarian cancers are associated with ovarian or pelvic endometriosis; a search for “42%” found no such estimate. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [21] Hitti, 1990, Clear cell carcinoma arising in extraovarian endometriosis: Report of three cases and review of the literature, Gynecol. Oncol. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, one-third of case reports in the literature of clear cell carcinoma arising in cesarean section scars were not associated with endometriosis near the tumor [24].”
§ Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review > 4. Discussion
What the sources say
- Supportedcites [24] Ferrandina, 2016, Endometriosis-associated clear cell carcinoma arising in caesarean section scar: A case report and review of the literature, World J. Surg. Oncol. source
The Discussion states that almost one third of clear cell carcinomas arising within caesarean-section scars were not associated with endometriosis foci (Table 1). It cautions that absent pathologically assessed foci do not rule out prior endometriosis, because some patients had suggestive symptoms or a history of excision. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It must be emphasized that 90% of malignant scar endometriosis have undergone previous gynecological procedures with endometrium exposure, including and not limited to cesarean sections, therefore making the translocation theory more plausible [31].”
§ Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review > 4. Discussion > 4.1. Plausible Theories
What the sources say
- Partly supportedcites [31] Bedell, 2020, Incisional carcinoma of Mullerian Origin: A case report and review of literature, Gynecol. Oncol. Rep. sourceExperimental — accuracy not yet measured
The Discussion > Origin reports that over 90% of patients with primary incisional carcinoma had undergone procedures with possible endometrial exposure and presents this as evidence for translocation. It does not establish that translocation is more plausible than another mechanism overall; it describes primary incisional carcinoma as the condition to be explained, not a competing theory. The cited figure also concerns patients with primary incisional carcinoma, rather than specifically malignant scar endometriosis. (LLM, conf=0.86)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Larger cohorts have shown an increased risk of cancer in women with endometriosis [18,34].”
§ Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review > 4. Discussion > 4.1. Plausible Theories
What the sources say
- Could not verifycites [18] Scholler, 2007, CA125 in ovarian cancer, Biomark. Med. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) mentions endometriosis only as a benign condition associated with elevated CA125. A search for endometriosis and cancer risk found no passage reporting that larger cohorts observed increased cancer risk in women with endometriosis. (LLM, conf=0.76)
- Partly supportedcites [34] Lai, Y.L., Hsu, H.C., Kuo, K.T., Chen, Y.L., Chen, C.A., and Cheng, W.F. (2019). Clear Cell Carcinoma of the Abdominal Wall as a Rare Complication of General Obstetric and Gynecologic Surgeries: 15 Years of Experience at a Large Academic Institution. Int. J. Environ. Res. Public Health, 16. sourceExperimental — accuracy not yet measured
The Introduction reports that cancers arise in an estimated 1% of women with ovarian endometriosis, and the Discussion describes studies linking endometriosis to ovarian clear cell carcinoma. But this paper reports a six-patient case series, not a larger cohort, and does not present a cohort comparison showing increased cancer risk in women with endometriosis generally. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
71 more claims · 17 with their cited sources checked
Create a free account to see all 150 claims and to verify the 2 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 39
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review > Abstract
“The main signs and symptoms were a palpable abdominal mass (85.2%) and cyclic pelvic pain (60.6%).”
§ Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review > 3. Results > 3.3. Clinical Manifestation
“The primary symptoms of malignant transformation of abdominal wall included an abdominal nodule, mass, or lump (37.0%), abdominal or pelvic pain (37.0%) and/or both (19.2%) (Table 2).”
Citations
Cites
ENDOMETRIAL CARCINOMA OF THE OVARY, ARISING IN ENDOMETRIAL TISSUE IN THAT ORGAN
SAMPSON, J. A. (1925) · Archives of Surgery · doi:10.1001/archsurg.1925.01120100007001 · Cited by 765 · cited 1×
“He proposed three criteria for the diagnosis of malignancy arising from endometriosis: (1) demonstration of benign and neoplastic endometrial tissues in the tumor, (2) the histology being compatible with endometrial origin, and (3) with no other discoverable primary tumor sites [6].”
BackgroundSmolarz, B., Szyłło, K., & Romanowicz, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910554 · Cited by 560 · cited 2×
“Endometriosis is a common condition which is estimated to occur in about 10–15% in women of reproductive age [1].”
BackgroundMalignancy in Endometriosis: Frequency and Comparison of Ovarian and Extraovarian Types
Stern, R. C., Dash, R., Bentley, R. C., Snyder, M. J., Haney, A. F., & Robboy, S. J. (2001) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200104000-00004 · Cited by 403 · cited 1×
“Malignant transformation is an extremely rare condition, and it is estimated to occur in 0.7 to 1.5% of all cases of endometriosis [8].”
BackgroundInfluentialAbdominal wall endometriosis: a surgeon's perspective and review of 445 cases
Horton, J. D., DeZee, K. J., Ahnfeldt, E. P., & Wagner, M. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.07.035 · Cited by 391 · cited 1×
“The probability of developing endometriosis on an abdominal surgical scar is 0.03% to 1% [13,14].”
BackgroundInfluentialYamaguchi, K., Mandai, M., Toyokuni, S., Hamanishi, J., Higuchi, T., Takakura, K., & Fujii, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1614 · Cited by 324 · cited 2×
“Yamaguchi et al. demonstrated that endometriotic cysts have an abundance of free iron that is strongly associated with frequent DNA mutations and may play a crucial role in the malignant transformation to ovarian cancers [46].”
BackgroundMalignant changes in endometriosis.
Rb, S. (1953) · PubMed · Cited by 296
Extrapelvic Endometriosis: A Systematic Review
Andres, M. P., Arcoverde, F. V. L., Souza, C. C. C., Fernandes, L. F. C., Abrão, M. S., & Kho, R. M. (2020) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2019.10.004 · Cited by 276 · cited 1×
“Deep endometriosis (DE) found in extra-pelvic sites could also be explained by other theories such as the celomic metaplasia theory, the embryonic cell and lymphatic dissemination theory [3].”
BackgroundOvarian and extraovarian endometriosis-associated cancer
Modesitt, S. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02149-x · Cited by 242 · cited 1×
“The study by Modesitt et al. (2002) noted the presence of “transition points” in such tumors, where a benign endometriotic gland was observed blending with atypical and overtly malignant glands [16].”
BackgroundScholler, N., & Urban, N. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.4.513 · Cited by 220 · cited 3×
“…in advanced-stage ovarian cancer, where its value increases along with tumor size and is useful for predicting responses to chemotherapy, disease progression and recurrence, serum CA125 does not seem to be a valuable marker for the diagnosis of malignant transformation of endometriosis [18,34].”
BackgroundESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: An update
Forstner, R., Thomassin-Naggara, I., Cunha, T. M., Kinkel, K., Masselli, G., Kubik-Huch, R., Spencer, J. A., & Rockall, A. (2017) · European Radiology · doi:10.1007/s00330-016-4600-3 · Cited by 204 · cited 1×
“Kawahara et al. (2021) published a formula that estimates R2 values by incorporating CEA and tumor diameters as independent predictive factors for discriminating endometriosis ovarian cancer, from ovarian endometrioma [20,51].”
Background
Cited by
Rectus Abdominis Muscle Endometriosis: A Unique Case Report with a Literature Review
Turčić, M., Matušan Ilijaš, K., Rajković Molek, K., & Valković Zujić, P. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47010047 · Cited by 6
“Immune cells, such as lymphocytes and monocytes/macrophages, play a significant role in immunomodulation and can either promote or inhibit the development of endometriosis, depending on their function.”
Primary Carcinomas of the Episiotomy Scar Site: A Systematic Literature Review
Palicelli, A., Torricelli, F., Tonni, G., Bisagni, A., Zanetti, E., Zanelli, M., Medina-Illueca, V. D., Melli, B., Zizzo, M., Morini, A., et al. (2025) · Current Oncology · doi:10.3390/curroncol32020065 · Cited by 7
“…(4.5% of extragonadal ERHs) and typically show estrogen receptors (ERs) downregulation with lack the immunohistochemical ER expression; moreover, mesonephric-like adenocarcinomas, a rare new entity which also downregulate ER and PR, can also exceptionally arise from endometriosis [69,73–84].”
InfluentialCo-existence of the abdominal wall and thoracic endometriosis: case report and literature review
Gao, B., Li, Z., Liu, H., Zhou, G., & Lai, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1578435 · Cited by 6
“%) at the surgical incision (17).”
Dayan, D., Wisniewski, L., Formentini, A., Kornmann, M., Bette, S., Ebner, F. K., Janni, W., Lukac, S., Traub, L., & Schochter, F. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03974-0 · Cited by 2
“The limited available evidence suggests a generally poor prognosis, with recurrence-free survival ranging from three to 93 months and a 5-year survival rate of approximately 40% [2, 29, 34].”
A Case of Clear Cell Carcinoma Associated with Abdominal Wall Endometriosis
艾, 日. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42223
Metadata
- Authors
- Alaert, J., Lancelle, M., Timmermans, M., Tanos, P., Nisolle, M., & Karampelas, S.
- Affiliations
- Université Libre de Bruxelles (BE)
- University of Liège (BE)
- Corresponding author
- Tanos, Panayiotis
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-04-15
- Volume
- 13
- Issue
- 8
- Pages
- 2282
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC11050881
- OpenAlex
- W4394798567
- Cited by
- 9
- References
- 114
- Citations by year
- 2026: 4 · 2025: 5
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- abdominal wall endometriosis, endometriosis-associated malignancy, scar endometriosis, malignant transformation, adjuvant chemotherapy, surgical resection, prognosis, relapse, cesarean section complications, endometriotic implants
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review. https://app.cochat.ai/papers/10.3390/jcm13082282
- The paper
- Alaert, J., Lancelle, M., Timmermans, M., Tanos, P., Nisolle, M., & Karampelas, S. (2024). Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13082282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
